DiaBridge AB
556979-7995ActiveDeveloping breakthrough drugs targeting DNA repair for cancer and inflammation.
Overview
- 0
- Employees
- ≤1K SEK
- Revenue
- 2014
- Founded
Key Decision Makers
Ulrika Warpman Berglund
CEO
Ingvar Karlsson
Member of the Board
Thomas Helleday
Member of the Board
Eva Sjökvist Saers
Chairman of the board
+5 more contacts in Funnelfeedr
Description
Oxcia AB is a science-led Swedish biotechnology company focused on revolutionizing treatments for cancer and inflammation. The core of their innovation lies in the unique O2-DDR technology platform, which manages oxidative stress, oxidative DNA damage, and the DNA Damage Response (DDR) in cells. Thi...
Tags
Keywords
Company Information
- Industry
- Annan naturvetenskaplig och teknisk forskning och utveckling
- Legal Form
- Aktiebolag
- VAT Number
- SE556979799501
Decision Makers
9 contacts in FunnelfeedrUlrika Warpman Berglund
CEO
Ingvar Karlsson
Member of the Board
Thomas Helleday
Member of the Board
Eva Sjökvist Saers
Chairman of the board
Austin Smith
Chief Medical Officer
Håkan Nordlander
Head Administration and Accounting
Gustaf Eriksson
Sales and Marketing Manager
Monika Vedin
Business strategy & Communication Director
Christina Kalderén
Preclinical Director
Similar Companies
20 similar companies in FunnelfeedrPILA PHARMA AB
1–4 employeesClinical stage biotech developing an oral obesity and diabetes treatment.
MyCural Therapeutics AB
10–19 employeesDeveloping novel small molecule therapies targeting the MYC oncoprotein.
Beactica Therapeutics AB
6 employeesPrecision medicine company developing novel therapeutics via targeted protein degradation.
Oncotech Nordic AB
0 employeesDeveloping AI diagnostics and immunotherapy to conquer global cancer.
One-carbon Therapeutics AB
Clinical-stage biotech pioneering novel anti-cancer therapies targeting metabolism.
Browse More
DiaBridge AB Questions
Want to see Funnelfeedr in action?
Book a free demo and discover how Funnelfeedr helps you find and convert your ideal customers.
Book a demo